Cargando…

Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India

The World Health Organization (WHO) has developed specific guidelines for critical concentrations (CCs) of antibiotics used for tuberculosis (TB) treatment, which is universally followed for drug susceptibility testing (DST) of clinical specimens. However, the CC of drugs can differ significantly am...

Descripción completa

Detalles Bibliográficos
Autores principales: Dusthackeer, Azger, Saadhali, Shainaba A., Thangam, Manonanthini, Hassan, Sameer, Balasubramanian, Mahizhaveni, Balasubramanian, Angayarkani, Ramachandran, Geetha, Kumar, A. K. Hemanth, Thiruvenkadam, Kannan, Shanmugam, Govindarajan, Nirmal, Christy Rosaline, Rajadas, Sam Ebenezer, Mohanvel, Sucharitha Kannappan, Mondal, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338667/
https://www.ncbi.nlm.nih.gov/pubmed/32695072
http://dx.doi.org/10.3389/fmicb.2020.01182
_version_ 1783554731348590592
author Dusthackeer, Azger
Saadhali, Shainaba A.
Thangam, Manonanthini
Hassan, Sameer
Balasubramanian, Mahizhaveni
Balasubramanian, Angayarkani
Ramachandran, Geetha
Kumar, A. K. Hemanth
Thiruvenkadam, Kannan
Shanmugam, Govindarajan
Nirmal, Christy Rosaline
Rajadas, Sam Ebenezer
Mohanvel, Sucharitha Kannappan
Mondal, Rajesh
author_facet Dusthackeer, Azger
Saadhali, Shainaba A.
Thangam, Manonanthini
Hassan, Sameer
Balasubramanian, Mahizhaveni
Balasubramanian, Angayarkani
Ramachandran, Geetha
Kumar, A. K. Hemanth
Thiruvenkadam, Kannan
Shanmugam, Govindarajan
Nirmal, Christy Rosaline
Rajadas, Sam Ebenezer
Mohanvel, Sucharitha Kannappan
Mondal, Rajesh
author_sort Dusthackeer, Azger
collection PubMed
description The World Health Organization (WHO) has developed specific guidelines for critical concentrations (CCs) of antibiotics used for tuberculosis (TB) treatment, which is universally followed for drug susceptibility testing (DST) of clinical specimens. However, the CC of drugs can differ significantly among the mycobacterial species based on the population, geographic location, and the prevalence of the infecting strain in a particular area. The association between CC and the minimal inhibitory concentration (MIC) of anti-TB drugs is poorly understood. In this study, we assessed the MICs of anti-TB drugs, including isoniazid (INH), rifampicin (RMP), moxifloxacin (MXF), ethambutol (ETH), and p-aminosalicylic acid (PAS) on drug-sensitive Mtb isolates from pulmonary TB patients in South India. The MIC assays performed using solid- and liquid-growth media showed changes in the CC of a few of the tested antibiotics compared with the WHO-recommended levels. Our observation suggests that the WHO guidelines could potentially lead to overdiagnosis of drug-resistant cases, which can result in inappropriate therapeutic decisions. To evaluate the correlation between drug-resistance and CC, we performed the whole-genome sequencing for 16 mycobacterial isolates, including two wild-type and 14 resistant isolates. Our results showed that two of the isolates belonged to the W-Beijing lineage, while the rest were of the East-African–Indian type. We identified a total of 74 mutations, including five novel mutations, which are known to be associated with resistance to anti-TB drugs in these isolates. In our previous study, we determined the serum levels of INH and RMP among the same patients recruited in the current study and estimated the MICs of the corresponding infected isolates in these cases. Using these data and the CCs for INH and RMP from the present study, we performed pharmacodynamics (PD) evaluation. The results show that the PD of RMP was subtherapeutic. Together, these observations emphasize the need for optimizing the drug dosage based on the PD of large-scale studies conducted in different geographical settings.
format Online
Article
Text
id pubmed-7338667
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73386672020-07-20 Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India Dusthackeer, Azger Saadhali, Shainaba A. Thangam, Manonanthini Hassan, Sameer Balasubramanian, Mahizhaveni Balasubramanian, Angayarkani Ramachandran, Geetha Kumar, A. K. Hemanth Thiruvenkadam, Kannan Shanmugam, Govindarajan Nirmal, Christy Rosaline Rajadas, Sam Ebenezer Mohanvel, Sucharitha Kannappan Mondal, Rajesh Front Microbiol Microbiology The World Health Organization (WHO) has developed specific guidelines for critical concentrations (CCs) of antibiotics used for tuberculosis (TB) treatment, which is universally followed for drug susceptibility testing (DST) of clinical specimens. However, the CC of drugs can differ significantly among the mycobacterial species based on the population, geographic location, and the prevalence of the infecting strain in a particular area. The association between CC and the minimal inhibitory concentration (MIC) of anti-TB drugs is poorly understood. In this study, we assessed the MICs of anti-TB drugs, including isoniazid (INH), rifampicin (RMP), moxifloxacin (MXF), ethambutol (ETH), and p-aminosalicylic acid (PAS) on drug-sensitive Mtb isolates from pulmonary TB patients in South India. The MIC assays performed using solid- and liquid-growth media showed changes in the CC of a few of the tested antibiotics compared with the WHO-recommended levels. Our observation suggests that the WHO guidelines could potentially lead to overdiagnosis of drug-resistant cases, which can result in inappropriate therapeutic decisions. To evaluate the correlation between drug-resistance and CC, we performed the whole-genome sequencing for 16 mycobacterial isolates, including two wild-type and 14 resistant isolates. Our results showed that two of the isolates belonged to the W-Beijing lineage, while the rest were of the East-African–Indian type. We identified a total of 74 mutations, including five novel mutations, which are known to be associated with resistance to anti-TB drugs in these isolates. In our previous study, we determined the serum levels of INH and RMP among the same patients recruited in the current study and estimated the MICs of the corresponding infected isolates in these cases. Using these data and the CCs for INH and RMP from the present study, we performed pharmacodynamics (PD) evaluation. The results show that the PD of RMP was subtherapeutic. Together, these observations emphasize the need for optimizing the drug dosage based on the PD of large-scale studies conducted in different geographical settings. Frontiers Media S.A. 2020-06-30 /pmc/articles/PMC7338667/ /pubmed/32695072 http://dx.doi.org/10.3389/fmicb.2020.01182 Text en Copyright © 2020 Dusthackeer, Saadhali, Thangam, Hassan, Balasubramanian, Balasubramanian, Ramachandran, Kumar, Thiruvenkadam, Shanmugam, Nirmal, Rajadas, Mohanvel and Mondal. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Dusthackeer, Azger
Saadhali, Shainaba A.
Thangam, Manonanthini
Hassan, Sameer
Balasubramanian, Mahizhaveni
Balasubramanian, Angayarkani
Ramachandran, Geetha
Kumar, A. K. Hemanth
Thiruvenkadam, Kannan
Shanmugam, Govindarajan
Nirmal, Christy Rosaline
Rajadas, Sam Ebenezer
Mohanvel, Sucharitha Kannappan
Mondal, Rajesh
Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
title Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
title_full Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
title_fullStr Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
title_full_unstemmed Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
title_short Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
title_sort wild-type mic distribution for re-evaluating the critical concentration of anti-tb drugs and pharmacodynamics among tuberculosis patients from south india
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338667/
https://www.ncbi.nlm.nih.gov/pubmed/32695072
http://dx.doi.org/10.3389/fmicb.2020.01182
work_keys_str_mv AT dusthackeerazger wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT saadhalishainabaa wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT thangammanonanthini wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT hassansameer wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT balasubramanianmahizhaveni wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT balasubramanianangayarkani wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT ramachandrangeetha wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT kumarakhemanth wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT thiruvenkadamkannan wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT shanmugamgovindarajan wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT nirmalchristyrosaline wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT rajadassamebenezer wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT mohanvelsucharithakannappan wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia
AT mondalrajesh wildtypemicdistributionforreevaluatingthecriticalconcentrationofantitbdrugsandpharmacodynamicsamongtuberculosispatientsfromsouthindia